The interaction between ATP13A2 and alpha-synuclein in mice
The interaction between ATP13A2 and alpha-synuclein in mice
批准号:
8320093
负责人:
Sheila Fleming
金额:
$23.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2014-05-31
关键词:
ATP phosphohydrolaseAccelerationAffectAgeAge-MonthsAutophagocytosisBehavioralBrainCell Culture TechniquesCell DeathCessation of lifeCrossbreedingDataDegradation PathwayDementiaDevelopmentDiseaseDisease ProgressionDopaminergic CellEnvironmentFamilyFunctional disorderGenesGeneticGoalsHumanImpairmentInheritedInterventionIon TransportKnockout MiceKnowledgeLaboratoriesLaboratory miceLeadLinkMeasuresMediatingMembrane ProteinsMissionModelingMolecular ChaperonesMusMutant Strains MiceMutationNeural PathwaysPARK9 geneParkinson DiseaseParkinsonian DisordersPathologicPathologyProgressive DiseaseProteinsPublic HealthPublishingResearchRodentRoleSensorimotor functionsSyndromeSystemTechniquesTestingToxic effectTreatment outcomeWorkalpha synucleinbasebehavioral impairmentcognitive functiondesigndisabilitydopaminergic neuronearly onsetfunctional disabilitygene discoveryimprovedin vivoinnovationloss of functionlysosomal proteinsmotor impairmentmutantneurochemistryneuromechanismnew therapeutic targetnigrostriatal systemnoveloverexpressionpresynapticpreventsynucleintherapeutic target
中文摘要
描述(由申请人提供):随着与帕金森病相关的新基因的不断鉴定,该领域的一个迫切问题是了解这些基因是否相互作用导致帕金森病的主要特征的发展。这种信息的缺乏是一个重要的问题,因为它限制了对帕金森病潜在共同机制的理解,从而也限制了新型疾病修饰疗法的发展。长期目标是通过确定可以预防或显著减缓疾病进展的新治疗靶点来改善帕金森病的治疗效果。这项特殊应用的目的是确定遗传位点ATP13A2 (PARK9)和α -突触核蛋白(PARK1)如何相互作用,特别是ATP13A2功能丧失如何影响小鼠α -突触核蛋白毒性。ATP13A2缺失和α -突触核蛋白过表达的小鼠都表现出与帕金森病相似的行为障碍和解剖病理,突出了它们的实用性。核心假设是ATP13A2功能丧失增强α -突触核蛋白毒性,导致体内多巴胺能细胞加速丧失和功能损伤。这一假设是根据申请人的实验室提出的初步和已发表的研究而制定的。提出这项研究的基本原理是,一旦确定了与细胞和行为功能障碍相关的病理机制,就可以开始开发潜在的治疗方法。在初步数据的指导下,我们将通过两个具体目标来验证这一假设:1)确定体内ATP13A2缺失与1-突触核蛋白负荷增强之间相互作用的功能效应。2)验证小鼠体内ATP13A2功能丧失合并α -突触核蛋白过表达导致溶酶体功能障碍,α -突触核蛋白异常积累增加,黑质纹状体多巴胺神经元死亡加速的假说。在第一个目标中,将由申请人实验室产生的ATP13A2无基因小鼠与过表达α -synuclein的小鼠进行杂交,产生过表达α -synuclein的双突变ATP13A2无基因小鼠。随着年龄的增长,这些小鼠将在申请人的实验室设计和建立的测试中接受行为障碍测试。在目标二中,免疫组织化学技术、神经化学分析和体视学技术的结合将用于测量多个年龄段的脑溶酶体蛋白、α -突触核蛋白和黑质纹状体病理。提出的方法是创新的,因为它侧重于体内环境中与帕金森病相关的两个遗传位点之间的相互作用。这项研究具有重要意义,因为它是一系列研究的第一步,有望导致PD发展机制的识别,并提供一个模型来测试针对这些机制的潜在治疗方法。
英文摘要
DESCRIPTION (provided by applicant): With the continued identification of novel genes associated with Parkinsonism an imperative question in the field is to know whether these genes interact to lead to the development of the cardinal features of Parkinson's disease. This lack of information is an important problem because it limits the understanding of potential common mechanisms underlying Parkinson's disease thus also limiting the development of novel disease-modifying treatments. The long-term goal is to improve treatment outcomes in Parkinson's disease by identifying novel therapeutic targets that can prevent or significantly slow the progression of the disease. The objective in this particular application is to determine how the genetic loci ATP13A2 (PARK9) and alpha-synuclein (PARK1) interact, specifically how does the loss of function of ATP13A2 affect alpha-synuclein toxicity in mice. ATP13A2 null and alpha-synuclein overexpressing mice each show aspects of behavioral impairment and anatomical pathology reminiscent of that seen in Parkinson's disease highlighting their usefulness. The central hypothesis is that loss of function of ATP13A2 enhances alpha-synuclein toxicity leading to accelerated dopaminergic cell loss and functional impairments in vivo. The hypothesis has been formulated on the basis of preliminary and published studies produced by the applicants' laboratories. The rationale for the proposed research is that once the pathologic mechanisms associated with cellular and behavioral dysfunction are identified, the development of potential therapies can be initiated. Guided by preliminary data this hypothesis will be tested by pursuing two specific aims: 1) Determine the functional effects of the interaction between loss of ATP13A2 and enhanced 1-synuclein protein burden in vivo. 2) To test the hypothesis that loss of function of ATP13A2 combined with overexpression of alpha-synuclein in mice leads to lysosomal dysfunction, increased abnormal accumulation of alpha-synuclein, and an acceleration of nigrostriatal dopamine neuron death in vivo. In the first aim, ATP13A2 null mice generated by the applicants' laboratory and mice that overexpress alpha-synuclein will be crossbred to generate double mutant ATP13A2 null mice that overexpress alpha-synuclein. These mice will be tested for behavioral impairments as they age on tests designed and established in the applicants' laboratories. In aim two, a combination of immunohistochemical techniques, neurochemical analysis, and stereological techniques will be used to measure brain lysosomal proteins, alpha-synuclein, and nigrostriatal pathology at multiple ages. The proposed approach is innovative, because it focuses on the interaction between two genetic loci linked to Parkinsonism in an in vivo environment. The proposed research is significant because it is the first step in a line of research expected to lead to the identification of mechanisms contributing to the development of PD and provide a model to test potential therapeutics targeting these mechanisms.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bbr.2018.01.029
发表时间:
2018-05-02
期刊:
Behavioural brain research
影响因子:
2.7
作者:
[Dirr ER, Ekhator OR, Blackwood R, Holden JG, Masliah E, Schultheis PJ, Fleming SM]
通讯作者:
Fleming SM
ATP13A2 and Susceptibility to Neurodegeneration
-
批准号:10641796
-
项目类别:
-
资助金额:$32.95万
-
财政年份:2020
-
负责人:Sheila Fleming
-
依托单位:
ATP13A2 and Susceptibility to Neurodegeneration
-
批准号:10271238
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2020
-
负责人:Sheila Fleming
-
依托单位:
ATP13A2 and Susceptibility to Neurodegeneration
-
批准号:10440477
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2020
-
负责人:Sheila Fleming
-
依托单位:
The interaction between ATP13A2 and alpha-synuclein in mice
-
批准号:8224462
-
项目类别:
-
资助金额:$19.63万
-
财政年份:2011
-
负责人:Sheila Fleming
-
依托单位:
海外基金